New FDA Approval for CML Patients

Asciminib (Scemblix) was recently approved for the following indications:

For patients with Philadelphia chromosome– positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have been previously treated with two or more tyrosine kinase inhibitors.

For patients with Ph+ CML in chronic phase with a T315I mutation

Here at Belong, we will continue to update you with new medical and research developments. If you are interested in clinical trial-related info or in participating in such a trial, you are invited to respond here or contact us in the “Find Clinical Trials” group.

Best of health,
The Clinical Trial Team

For more info:

This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service or treatment

Hidden Hardships Patients Face and How to Cope

Managing your health can feel overwhelming, like a full-time job. Between appointments, medications, and lifestyle…

The Intersection of Food Allergies and MS

While the research is still evolving, some studies suggest that individuals with MS may experience…

How Cancer Treatments Affect the Heart

Cancer treatments can impact heart health in various ways, either during treatment or years later…

The JC Virus Decoded

Don’t let its cryptic name fool you, this tiny agent has significant implications for those…

Cold Sensitivity: Tips to Stay Warm

Are you struggling to stay warm this winter due to cold sensitivity? Cold dysesthesia is…

5 tips for coping with anxiety

If you experience occasional anxiety, quick techniques can help you regain control. These strategies are…